Associations - GNAQ mutation

GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	binimetinib + STA-4783 Sensitive: D – Preclinical Oncogene - 1 week (New D)	binimetinib + STA-4783 Sensitive: D – Preclinical Oncogene - 1 week - (New D)
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	STA-4783 Sensitive: D – Preclinical Oncogene - 1 week (New D)	STA-4783 Sensitive: D – Preclinical Oncogene - 1 week - (New D)
GNAQ mutation GNAQ mutation	Melanoma Melanoma	GNAQ mutation GNAQ mutation	Melanoma Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria	selumetinib Sensitive: C2 – Inclusion Criteria
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	trametinib Sensitive: C2 – Inclusion Criteria	trametinib Sensitive: C2 – Inclusion Criteria
GNAQ mutation GNAQ mutation	Melanoma Melanoma	GNAQ mutation GNAQ mutation	Melanoma Melanoma	vorinostat Sensitive: C2 – Inclusion Criteria	vorinostat Sensitive: C2 – Inclusion Criteria
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	cabozantinib capsule Sensitive: C3 – Early Trials	cabozantinib capsule Sensitive: C3 – Early Trials
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	AEB071 Sensitive: C3 – Early Trials	AEB071 Sensitive: C3 – Early Trials
GNAQ mutation GNAQ mutation	Renal Cell Carcinoma RCC	GNAQ mutation GNAQ mutation	Renal Cell Carcinoma RCC	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
GNAQ mutation GNAQ mutation	Melanoma Melanoma	GNAQ mutation GNAQ mutation	Melanoma Melanoma	trametinib + dabrafenib Sensitive: C3 – Early Trials	trametinib + dabrafenib Sensitive: C3 – Early Trials
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	AEB071 + AHT956 Sensitive: D – Preclinical	AEB071 + AHT956 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	Tris DBA Sensitive: D – Preclinical	Tris DBA Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	FR900359 Sensitive: D – Preclinical	FR900359 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	AEB071 + CGM097 Sensitive: D – Preclinical	AEB071 + CGM097 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	everolimus + AEB071 Sensitive: D – Preclinical	everolimus + AEB071 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	binimetinib + AEB071 Sensitive: D – Preclinical	binimetinib + AEB071 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	JQ-1 Sensitive: D – Preclinical	JQ-1 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	PD-0325901 + AEB071 Sensitive: D – Preclinical	PD-0325901 + AEB071 Sensitive: D – Preclinical